Abstract
Nalbuphine, a kappa-opioid agonist and mu-opioid partial agonist, has been widely used as an analgesic or an adjuvant with morphine in clinics. In rats, it attenuates tolerance and physical dependence caused by morphine, when co-administered. In this study, we investigated the effect of nalbuphine on morphine reward. Using the conditioned place preference (CPP) paradigm in rats, we demonstrated that co-administration of nalbuphine (1mg/kg, i.p.) with morphine (5mg/kg, i.p.) during conditioning could completely block the CPP induced by morphine. However, in experiments examining locomotor activity in rats, nalbuphine showed no effect on the development of behavioral sensitization induced by reported morphine administration. In microdialysis experiments, morphine induced a significant increase in the dopamine metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid in the shell region of the nucleus accumbens. Co-administration of nalbuphine blocked the increase in dopamine metabolites induced by morphine. These results may be due to the attenuating effect of nalbuphine on the dopaminergic activity of mesolimbic pathways. All of these results suggest nalbuphine could have a great potential as a pharmacotherapy for opiate ...Continue Reading
References
Mar 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R SpanagelT S Shippenberg
Mar 1, 1991·Drugs·P J Hoskin, G W Hanks
Sep 1, 1983·Drugs·J K Errick, R C Heel
Dec 1, 1993·Neuropharmacology·M FunadaH Nagase
Sep 1, 1993·Brain Research. Brain Research Reviews·T E Robinson, K C Berridge
Mar 1, 1997·Neuroscience·D L CameronJ T Williams
Mar 5, 1997·European Journal of Pharmacology·A V KuzminJ M Van Ree
Apr 1, 1997·Anesthesia and Analgesia·S C LeeP L Tao
Oct 17, 1998·Regional Anesthesia and Pain Medicine·J J WangJ I Tzeng
Oct 23, 1998·Psychopharmacology·M MarinelliP V Piazza
Jan 1, 1999·Progress in Neurobiology·T M Tzschentke
May 27, 1999·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·R Ciccocioppo
Oct 27, 1999·Pain·R W GearJ D Levine
Apr 24, 2001·Pharmacology & Therapeutics·M NaritaT Suzuki
Dec 26, 2001·The Journal of Pharmacology and Experimental Therapeutics·John R TraynorAnn E Remmers
Apr 23, 2003·Trends in Pharmacological Sciences·Antonello BonciNicola B Mercuri
Oct 18, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Eagle Y-K HuangPao-Luh Tao
Jul 17, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Minoru NaritaTsutomu Suzuki
Oct 7, 2004·Neuropharmacology·Gaetano Di ChiaraDaniele Lecca
Oct 7, 2004·Neuropharmacology·David W Self
Nov 16, 2004·Annals of the New York Academy of Sciences·Ko HasebeTsutomu Suzuki
Mar 22, 2005·Psychopharmacology·Mark A SmithDavid L Yancey
Nov 10, 2005·Brain Research. Brain Research Reviews·Hélène N DavidJacques H Abraini
Citations
Jun 23, 2011·Frontiers of Medicine·Jisheng HanLiuzhen Wu
Aug 7, 2007·Addiction Biology·Thomas M Tzschentke
May 3, 2012·Pain Research and Treatment·Richard H RechShannon L Briggs
Feb 8, 2014·Der Anaesthesist·A-M Schultz-MachataM Weiss
Dec 25, 2010·Neuroscience and Biobehavioral Reviews·Robert HuberJaak Panksepp
Sep 30, 2008·Behavioural Brain Research·Thomas I NathanielRobert Huber
Apr 30, 2008·Brain Research·Yao-Ying MaCai-Lian Cui
Oct 24, 2007·Peptides·Richard J Bodnar
Apr 7, 2015·European Journal of Pharmacology·Rasha Abdel-GhanyWaleed Barakat
Jun 28, 2016·European Journal of Pharmacology·Karine RoversiMarilise Escobar Burger
Jul 28, 2019·British Journal of Pharmacology·Lucja KudlaRyszard Przewlocki
Sep 8, 2019·The Journal of Pharmacology and Experimental Therapeutics·Shane W KaskiVincent Setola
Dec 18, 2020·Anesthesia and Analgesia·Shane W KaskiDavid P Siderovski
Mar 4, 2021·Psychopharmacology·Rahul RaghavTara S Roy
Apr 10, 2021·Pharmacological Reports : PR·Lucja Kudla, Ryszard Przewlocki
Oct 13, 2018·Pharmacology, Biochemistry, and Behavior·Rahul RaghavPunit Kumar
May 21, 2021·The Journal of Pharmacology and Experimental Therapeutics·Beth YoungbloodNeil Schwartz